1.5(top 50%)
impact factor
13.2K(top 2%)
196.1K(top 2%)
107(top 5%)
1.5(top 50%)
extended IF
all documents
doc citations
142(top 5%)

Top Articles

1Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and ManagementLeukemia and Lymphoma2000311
2CD19 Antigen in Leukemia and Lymphoma Diagnosis and ImmunotherapyLeukemia and Lymphoma1995275
3Triptolide, A Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook FLeukemia and Lymphoma2001269
4Management of adverse events associated with idelalisib treatment: expert panel opinionLeukemia and Lymphoma2015268
5Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in ChinaLeukemia and Lymphoma2002255
6Granulocytic sarcoma: 32 cases and review of the literatureLeukemia and Lymphoma2006247
718-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CTLeukemia and Lymphoma2000244
8Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaLeukemia and Lymphoma2013236
9Rituximab-related viral infections in lymphoma patientsLeukemia and Lymphoma2007235
10Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinibLeukemia and Lymphoma2008233
11Preclinicalversusclinical drug combination studiesLeukemia and Lymphoma2008233
12Pathways and mechanisms of venetoclax resistanceLeukemia and Lymphoma2017203
13Improved Outcome of Zygomycosis in Patients with Hematological Diseases?Leukemia and Lymphoma2004202
14Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP ChemotherapyLeukemia and Lymphoma2003199
15Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia and Lymphoma2011199
16Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelLeukemia and Lymphoma2011198
17Epidemiology of myeloproliferative neoplasms in the United StatesLeukemia and Lymphoma2014195
18Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia and Lymphoma2004193
19Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphomaLeukemia and Lymphoma2010187
20Renal failure in multiple myeloma: Incidence, correlations, and prognostic significanceLeukemia and Lymphoma2007186
21Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myelomaLeukemia and Lymphoma2008185
22Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?Leukemia and Lymphoma2017181
23Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic LeukemiaLeukemia and Lymphoma2002180
24Mastocytosis: Pathology, genetics, and current options for therapyLeukemia and Lymphoma2005180
25Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemiaLeukemia and Lymphoma2008176
26Primary Non-Hodgkin's Lymphoma of the LiverLeukemia and Lymphoma1998175
27Asparaginase-associated toxicity in children with acute lymphoblastic leukemiaLeukemia and Lymphoma2016175
28L-Asparaginase and PEG Asparaginase— Past, Present, and FutureLeukemia and Lymphoma1993174
29The Cytogenetic Scenario of Chronic Myeloid LeukemiaLeukemia and Lymphoma1993171
30Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT LymphomaLeukemia and Lymphoma1997171
31Targeting the apoptosis pathway in hematologic malignanciesLeukemia and Lymphoma2014169
32Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaLeukemia and Lymphoma2002163
33Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell StimulationLeukemia and Lymphoma2004162
34Apoptosis Overview Emphasizing the Role of Oxidative Stress, DNA Damage and Signal- Transduction PathwaysLeukemia and Lymphoma1995161
35Serum β2-Microglobulin and Serum Thymidine Kinase are Independent Predictors of Progression-Free Survival in Chronic Lymphocytic Leukemia and ImmunocytomaLeukemia and Lymphoma1996161
36Recent Results on the Biology of Hodgkin and Reed-Sternberg cells: II. Continuous Cell LinesLeukemia and Lymphoma1993157
37Rituximab in chronic cold agglutinin disease: a prospective study of 20 patientsLeukemia and Lymphoma2006157
38A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemiaLeukemia and Lymphoma2015155
39Ovarian Injury and Modern Options to Preserve Fertility in Female Cancer Patients Treated with High Dose Radio-Chemotherapy for Hemato-Oncological Neoplasias and other CancersLeukemia and Lymphoma1999153
40Skin lesions in chronic lymphocytic leukemiaLeukemia and Lymphoma2007152
41Bone marrow-derived mesenchymal stem cellsLeukemia and Lymphoma2005151
42Integrin-Mediated Drug Resistance in Multiple MyelomaLeukemia and Lymphoma2000149
43Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failureLeukemia and Lymphoma2013149
44Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous LeukemiaLeukemia and Lymphoma1993147
45Abnormal T-cell Function in B-cell Chronic Lymphocytic LeukaemiaLeukemia and Lymphoma2003145
46Regulation of Hematopoiesis by Microvascular EndotheliumLeukemia and Lymphoma1997144
47Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapyLeukemia and Lymphoma2008144
48Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonatesLeukemia and Lymphoma2008143
49Enhancer of zeste homolog 2 (EZH2) inhibitorsLeukemia and Lymphoma2018143
50Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignanciesLeukemia and Lymphoma2006140